V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.

Coave Therapeutics: redecorating viral vectors for improved gene therapies

Coave Therapeutics is a French biotech developing gene therapies for neurodegenerative and ocular diseases. The company has developed a technology […] January 25, 2023 · V-Bio Ventures

Why diversity matters in management teams, and how to achieve it

The biotech industry is suffering from a serious talent shortage, with start-ups in particular having an increasingly hard time filling […] December 14, 2022 · V-Bio Ventures

Cancer vaccines: not only treating tumors, but preventing them too

The COVID-19 pandemic has brought vaccines back into the drug development spotlight, and mRNA vaccines are stealing the show with […] November 23, 2022 · V-Bio Ventures

We need more food and agtech start-ups – and we need them now!

How are we going to feed an expected 10 billion people by 2050 in a sustainable way? It is a […] October 19, 2022 · V-Bio Ventures

V-Bio Ventures leads Sibylla Biotech's EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases

Ghent, Belgium, 4 October 2022 – V-Bio Ventures announces the successful close of a EUR 23 million Series A financing […] October 4, 2022 · V-Bio Ventures

VC opportunities for impact in the face of climate disaster

Venture capitalists have a vital role to play in guiding our planet’s future. By investing in technological advances that remediate […] September 7, 2022 · V-Bio Ventures

V-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain

Ghent, Belgium, 31 August 2022 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain […] August 31, 2022 · V-Bio Ventures

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

• Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs […] August 25, 2022 · V-Bio Ventures

Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease

Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The […] August 17, 2022 · V-Bio Ventures

Is the dot-com bubble bursting all over again?

The stock market value of biotech companies has been crashing lately, bitterly reminiscent of the dot-com bubble burst in the […] June 14, 2022 · V-Bio Ventures

Dualyx: restoring the body’s balance in autoimmune diseases

Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The […] May 12, 2022 · V-Bio Ventures

Drug development trends: from common to orphan indications… and back again?

Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to […] April 20, 2022 · V-Bio Ventures

V-Bio Ventures raises EUR 110 million for its second fund and expands team

Ghent, Belgium, 31 March 2022 – V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having […] March 31, 2022 · V-Bio Ventures

Antimicrobial Resistance – the hidden killer we’re ignoring

Antimicrobial Resistance has become an enormous challenge for global health, yet remains largely ignored by companies. As this deadly race […] March 16, 2022 · V-Bio Ventures

V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals

Ghent, Belgium, 16 March 2022 – V-Bio Ventures today announced the completion of a EUR 80 million Series B round […] March 16, 2022 · V-Bio Ventures